|
R S S F e e d s |
|
Clinical Trials / Drug Trials News From Medical News Today
|
Latest Clinical Trials / Drug Trials News From Medical News Today.
|
-
CaridianBCT Initiates Clinical Trial For Whole Blood Process With Mirasol® Pathogen Reduction Technology
CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic systems, whole blood processes and pathogen reduction technologies, announced today that it has initiated a clinical trial for treating whole blood with Mirasol Pathogen Reduction Technology (PRT) after receiving clearance from the U.S. Food and Drug Administration (FDA) and U.S. Department of Defense.
-
National Institutes Of Health Launches ClinicalTrials.gov Results Database
The National Institutes of Health (NIH) announced an expanded ClinicalTrials.gov database. The database will accept basic results information, in addition to trial registrations.
-
Leading US Phase I Cancer Center Opens Site In Madrid, Spain - START Center For Cancer Care
Texas-based START Center for Cancer Care today announced the establishment of a new global cancer research network, headquartered in San Antonio, that will make possible a dedicated, round-the- clock network of START Centers dedicated to Phase I cancer clinical trials, with the single-minded objective to accelerate the implementation of new anticancer therapies from discovery.
-
First Comprehensive Results From The UPLIFT Trial Revealed At The ERS Annual Congress In Berlin - Authors Reaffirm Tiotropium's Safety
The UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) study is a randomized double-blind, parallel-group, 4-year trial. One of the largest COPD trials ever undertaken, UPLIFT was aimed at comparing treatment with tiotropium once daily to placebo in COPD patients. It involved 5,993 patients, aged 65±8 years, with a FEV1 of 1.32± 0.44 L, followed in 470 sites and 37 countries. Three out of four patients were men and 30% current smokers.
-
ArQule Achieves Clinical Milestone In MiT Trial With ARQ 197 - Confirmed Tumor Response In Clear Cell Sarcoma Leads To Expanded Trial
ArQule, Inc. (NASDAQ: ARQL) today announced the expansion of its Phase 2 trial with ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase, in MiT (Microphthalmia Transcription Factor)-associated tumors based on the achievement of a partial response, as defined by RECIST (Response Evaluation Criteria in Solid Tumors), in a patient with clear cell sarcoma.
|
|
R S S F e e d s 
